Stryker Corporation $SYK Shares Bought by Advisory Alpha LLC

Advisory Alpha LLC raised its holdings in Stryker Corporation (NYSE:SYK) by 4.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,391 shares of the medical technology company’s stock after acquiring an additional 151 shares during the quarter. Advisory Alpha LLC’s holdings in Stryker were worth $1,342,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Rossby Financial LCC lifted its holdings in Stryker by 40.6% in the 2nd quarter. Rossby Financial LCC now owns 308 shares of the medical technology company’s stock valued at $122,000 after acquiring an additional 89 shares during the last quarter. Wealth Watch Advisors INC lifted its holdings in Stryker by 94.4% in the 2nd quarter. Wealth Watch Advisors INC now owns 6,453 shares of the medical technology company’s stock valued at $2,553,000 after acquiring an additional 3,134 shares during the last quarter. Schmidt P J Investment Management Inc. lifted its holdings in Stryker by 4.8% in the 2nd quarter. Schmidt P J Investment Management Inc. now owns 22,441 shares of the medical technology company’s stock valued at $8,878,000 after acquiring an additional 1,038 shares during the last quarter. CCLA Investment Management lifted its holdings in Stryker by 7.7% in the 2nd quarter. CCLA Investment Management now owns 348,812 shares of the medical technology company’s stock valued at $137,937,000 after acquiring an additional 24,822 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC lifted its holdings in Stryker by 9.2% in the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 23,214 shares of the medical technology company’s stock valued at $9,204,000 after acquiring an additional 1,962 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of analyst reports. Truist Financial reduced their price objective on shares of Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research note on Wednesday, October 15th. BTIG Research raised their target price on shares of Stryker from $407.00 to $408.00 and gave the stock a “buy” rating in a report on Monday, October 13th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Rothschild & Co Redburn started coverage on shares of Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Finally, Needham & Company LLC raised their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $432.24.

Stryker Price Performance

NYSE SYK opened at $376.11 on Wednesday. The company has a 50 day simple moving average of $379.59 and a 200-day simple moving average of $380.49. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a market capitalization of $143.79 billion, a price-to-earnings ratio of 49.82, a price-to-earnings-growth ratio of 2.76 and a beta of 0.94. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio is 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.